GAPDH with NAD+-binding site mutation competitively inhibits the wild-type and affects glucose metabolism in cancer.

Abstract excerpt

BACKGROUND: Rapid utilization of glucose is a metabolic signature of majority of cancers, hence enzymes of the glycolytic pathway remain attractive therapeutic targets. Recent reports have shown that targeting the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an abundant, ubiquitous multifunctional protein frequently upregulated in cancer, affects cancer progression. Here, we report that a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Catalysis
• Share to Cell Line, Tumor